A prospective controlled study of a computer-assisted acenocoumarol dosage program

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 2, 2003, Pages 59-63

  Marco, Fernando ^b   Sedano, Carmen ^a   Bermúdez, Arancha ^a   López Duarte, Mónica ^a   Fernández Fontecha, Elena ^a   Zubizarreta, Alberto ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

Author keywords

Acenocoumarol; Computer assisted dosage; International normalised ratio; Oral anticoagulants; Therapeutic quality

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COMPUTER ANALYSIS; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; FEMALE; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; MEDICAL STAFF; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VALIDATION PROCESS;

ACENOCOUMAROL; ADMINISTRATION, ORAL; AGE FACTORS; AGED; ANTICOAGULANTS; BODY WEIGHT; DRUG THERAPY, COMPUTER-ASSISTED; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; SEX FACTORS; TREATMENT OUTCOME;

EID: 0345356219     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073847     Document Type: Article

References (24)

1. British Society for Haematology: Guidelines on Oral Anticoagulation, ed 3. Br J Haematol 1998;101:374-387.
2. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D: Oral anticoagulants. Mechanisms of action, clinical effectiveness and optimal therapeutic range (review). Chest 2001;119(suppl):8S-21S.
3. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH: Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimised Outpatient Follow-up Study Group. Ann Intern Med 1993;118:511-520.
4. Galloway MJ, Foggin JJ, Dixon S: Introduction of computer-assisted control of oral anticoagulation in general practice. J Clin Pathol 1995;48:1144-1146.
5. Barbui T, Finazzi G, Remuzzi A: Clinical anticoagulation laboratory and oral anticoagulant therapy treatment. Instrumental and methodology. Thromb Haemost 1995;74:511-514.
6. Taylor F, Ramsay M, Covell B, Gaminara L, Thomson D, Cohen H, et al: Management of expanding anticoagulant clinics: A role for general practitioners? Br J Haematol 1994;86:68.
7. Poller L, Wright D, Rowlands M: Prospective comparative study of computer programs used for management of warfarin. J Clin Pathol 1993;46:299-303.
8. Vadher B, Patterson DLH, Leaning M: Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. BMJ 1997;314:1252-1256.
9. Fitzmaurice DA, Hobbs FDR, Delaney BC, Wilson S, MacManus R: Review of computerised decision support systems for oral anticoagulation management. Br J Haematol 1998;102:907-909.
10. Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE: Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: A randomized, controlled trial. Arch Intern Med 2000;160:2343-2348.
11. Poller L, Shiach CR, MacCallum PK, Johansen AM, Magalhaes A, Jespersen J: Multicentre randomised study of computerised anticoagulant dosage. Lancet 1998;352:1505-1509.
12. Palareti G: A guide to oral anticoagulant therapy. Italian Federation of Anticoagulation Clinics. Haemostasis 1998;28(suppl 1):1-46.
13. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briët E: A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239.
14. Hutten BA, Prins MH, Redekop WK, Tijssen JGP, Heisterkamp SH, Büller HR: Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists. Thromb Haemost 1999;82:1260-1263.
15. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S, on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy: Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423-428.
16. Palareti G, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Leali N, Poggi M, Legnani C, Musolesi S, Coccheri S, on behalf of the ISCOAT Study Group (Italian Study on Complications of Oral Anticoagulant Therapy): Thrombotic events during oral anticoagulant treatment: Results of the inception-cohort, prospective, collaborative ISCOAT study. Thromb Haemost 1997;78:1438-1443.
17. Kumar S, Haigh JRM, Rhodes LE, Peaker S, Davies JA, Roberts BE, Feely MP: Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thromb Haemost 1989;62:729-732.
18. Wells PS, Holbrook AM, Crowther NR, Hirsh J: Interaction of warfarin with drugs and food. Ann Intern Med 1994;121:676-683.
19. Sorano GG, Biondi G, Conti M, Mameli G, Licheri D, Marongiu F: Controlled vitamin K content in diet for improving the management of poorly controlled anticoagulated patients: A clinical practice proposal. Haemostasis 1993;23:77-82.
20. Manotti C, Quintavalla R, Pattacini C, Tagliaferri A, Pini M: Evaluation of a computer-assisted dosage prediction method for oral anticoagulant therapy. Thromb Haemost 1997;Suppl 699.
21. Azar AJ, Deckers JW, Rosendaal FR, van Bergen PF, van der Meer FJM, Jonker JJC, Briëf E: Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients. Thromb Haemost 1994;72:347-351.
22. Cortelazzo S, Finazzi G, Viero P, Galli M, Remuzzi A, Parenzan L, Barbui T: Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993;69:316-320.
23. Fitzmaurice DA, Hobbs FD, Murray ET: Primary care anticoagulant clinic management using computerised decision support and near patient International Normalised Ratio (INR) testing: Routine data from a practice nurse-led clinic. Fam Pract 1998;15:144-146.
24. Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hägg A, Jonsson T, Lapidus L, Leijd B, Stockelberg D, Säfwenberg U, Taghavi A, Thorsen M: Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999;81:358-363.